Logo image of ALTME.PA

TME PHARMA NV (ALTME.PA) Stock Fundamental Analysis

EPA:ALTME - Euronext Paris - Matif - NL0015000YE1 - Common Stock - Currency: EUR

0.083  0 (-0.24%)

Fundamental Rating

1

Overall ALTME gets a fundamental rating of 1 out of 10. We evaluated ALTME against 71 industry peers in the Biotechnology industry. The financial health of ALTME is average, but there are quite some concerns on its profitability. ALTME has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ALTME had negative earnings in the past year.
In the past year ALTME has reported a negative cash flow from operations.
ALTME had negative earnings in each of the past 5 years.
In the past 5 years ALTME always reported negative operating cash flow.
ALTME.PA Yearly Net Income VS EBIT VS OCF VS FCFALTME.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

With a Return On Assets value of -168.00%, ALTME is not doing good in the industry: 81.69% of the companies in the same industry are doing better.
ALTME's Return On Equity of -354.52% is on the low side compared to the rest of the industry. ALTME is outperformed by 64.79% of its industry peers.
Industry RankSector Rank
ROA -168%
ROE -354.52%
ROIC N/A
ROA(3y)-242.38%
ROA(5y)-194.56%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALTME.PA Yearly ROA, ROE, ROICALTME.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K 1.5K 2K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ALTME so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALTME.PA Yearly Profit, Operating, Gross MarginsALTME.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10K -20K -30K -40K

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, ALTME has more shares outstanding
ALTME has more shares outstanding than it did 5 years ago.
There is no outstanding debt for ALTME. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ALTME.PA Yearly Shares OutstandingALTME.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
ALTME.PA Yearly Total Debt VS Total AssetsALTME.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

Based on the Altman-Z score of -83.21, we must say that ALTME is in the distress zone and has some risk of bankruptcy.
ALTME has a worse Altman-Z score (-83.21) than 90.14% of its industry peers.
ALTME has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -83.21
ROIC/WACCN/A
WACCN/A
ALTME.PA Yearly LT Debt VS Equity VS FCFALTME.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M -10M

2.3 Liquidity

ALTME has a Current Ratio of 1.88. This is a normal value and indicates that ALTME is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of ALTME (1.88) is comparable to the rest of the industry.
A Quick Ratio of 1.88 indicates that ALTME should not have too much problems paying its short term obligations.
ALTME has a Quick ratio (1.88) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 1.88
Quick Ratio 1.88
ALTME.PA Yearly Current Assets VS Current LiabilitesALTME.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

0

3. Growth

3.1 Past

ALTME shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 88.76%, which is quite impressive.
EPS 1Y (TTM)88.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%87.97%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ALTME will show a very negative growth in Earnings Per Share. The EPS will decrease by -42.66% on average per year.
The Revenue is expected to decrease by -25.99% on average over the next years. This is quite bad
EPS Next Y-64.91%
EPS Next 2Y-42.66%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-25%
Revenue Next 2Y-13.4%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A

3.3 Evolution

ALTME.PA Yearly Revenue VS EstimatesALTME.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2024 2025 2026 100K 200K 300K
ALTME.PA Yearly EPS VS EstimatesALTME.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 -200 -400 -600

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ALTME reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALTME. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALTME.PA Price Earnings VS Forward Price EarningsALTME.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALTME.PA Per share dataALTME.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2 -0.3 -0.4

4.3 Compensation for Growth

A cheap valuation may be justified as ALTME's earnings are expected to decrease with -42.66% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-42.66%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ALTME does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TME PHARMA NV

EPA:ALTME (6/2/2025, 7:00:00 PM)

0.083

0 (-0.24%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.6%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap7.82M
Analysts84
Price Target0.38 (357.83%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-5.13%
PT rev (3m)-5.13%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.84
P/tB 4.86
EV/EBITDA N/A
EPS(TTM)-0.17
EYN/A
EPS(NY)-0.48
Fwd EYN/A
FCF(TTM)-0.05
FCFYN/A
OCF(TTM)-0.05
OCFYN/A
SpS0
BVpS0.02
TBVpS0.02
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -168%
ROE -354.52%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-242.38%
ROA(5y)-194.56%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 20.51%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.88
Quick Ratio 1.88
Altman-Z -83.21
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)18.84%
Cap/Depr(5y)27.5%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)88.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%87.97%
EPS Next Y-64.91%
EPS Next 2Y-42.66%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-25%
Revenue Next 2Y-13.4%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A
EBIT growth 1Y11.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-154.54%
EBIT Next 3Y75.05%
EBIT Next 5YN/A
FCF growth 1Y17.76%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y17.76%
OCF growth 3YN/A
OCF growth 5YN/A